Elanco Animal Health (ELAN) Stock Price, News & Analysis

-0.40 (-3.01%)
(As of 10:58 AM ET)
Today's Range
50-Day Range
52-Week Range
391,117 shs
Average Volume
4.36 million shs
Market Capitalization
$6.38 billion
P/E Ratio
Dividend Yield
Price Target

Elanco Animal Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
27.9% Upside
$16.71 Price Target
Short Interest
2.52% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.60mentions of Elanco Animal Health in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$322,800 Bought Last Quarter
Proj. Earnings Growth
From $0.91 to $1.04 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.00 out of 5 stars

Medical Sector

203rd out of 907 stocks

Pharmaceutical Preparations Industry

80th out of 422 stocks

ELAN stock logo

About Elanco Animal Health Stock (NYSE:ELAN)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

ELAN Stock Price History

ELAN Stock News Headlines

Elanco Animal Health (NYSE:ELAN) Shares Down 4.6%
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
The 4 best fish oils for dogs of 2024
Elanco Animal Health Inc
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Breaking Down Elanco Animal Health: 6 Analysts Share Their Views
Q4 2023 Elanco Animal Health Inc Earnings Call
See More Headlines
Receive ELAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elanco Animal Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$4.42 billion
Cash Flow
$2.22 per share
Book Value
$12.63 per share


Free Float
Market Cap
$6.42 billion
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

ELAN Stock Analysis - Frequently Asked Questions

Should I buy or sell Elanco Animal Health stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elanco Animal Health in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ELAN shares.
View ELAN analyst ratings
or view top-rated stocks.

What is Elanco Animal Health's stock price target for 2024?

7 brokerages have issued 1-year target prices for Elanco Animal Health's stock. Their ELAN share price targets range from $12.00 to $20.00. On average, they predict the company's share price to reach $16.71 in the next year. This suggests a possible upside of 27.9% from the stock's current price.
View analysts price targets for ELAN
or view top-rated stocks among Wall Street analysts.

How have ELAN shares performed in 2024?

Elanco Animal Health's stock was trading at $14.90 at the beginning of 2024. Since then, ELAN shares have decreased by 12.3% and is now trading at $13.07.
View the best growth stocks for 2024 here

Are investors shorting Elanco Animal Health?

Elanco Animal Health saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 12,980,000 shares, a decline of 5.2% from the February 29th total of 13,690,000 shares. Based on an average trading volume of 4,340,000 shares, the days-to-cover ratio is presently 3.0 days.
View Elanco Animal Health's Short Interest

When is Elanco Animal Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ELAN earnings forecast

How can I listen to Elanco Animal Health's earnings call?

Elanco Animal Health will be holding an earnings conference call on Wednesday, May 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health Incorporated (NYSE:ELAN) released its quarterly earnings data on Monday, February, 26th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.10 by $0.02. The company earned $1.04 billion during the quarter, compared to the consensus estimate of $1 billion. Elanco Animal Health had a positive trailing twelve-month return on equity of 6.44% and a negative net margin of 27.87%. The firm's revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.19 earnings per share.

What guidance has Elanco Animal Health issued on next quarter's earnings?

Elanco Animal Health issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 0.870-0.950 for the period, compared to the consensus EPS estimate of 0.890. The company issued revenue guidance of $4.5 billion-$4.5 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Jeff Simmons' approval rating as Elanco Animal Health's CEO?

169 employees have rated Elanco Animal Health Chief Executive Officer Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), Walt Disney (DIS), Johnson & Johnson (JNJ), AT&T (T), Cisco Systems (CSCO), CVS Health (CVS) and Bristol-Myers Squibb (BMY).

When did Elanco Animal Health IPO?

Elanco Animal Health (ELAN) raised $1.4 billion in an IPO on Thursday, September 20th 2018. The company issued 62,900,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's stock is owned by a variety of retail and institutional investors. Top institutional investors include Douglas Lane & Associates LLC (0.79%), Raymond James & Associates (0.25%), Perpetual Ltd (0.21%), Assenagon Asset Management S.A. (0.19%), Sanders Morris Harris LLC (0.08%) and Raymond James Financial Services Advisors Inc. (0.05%). Insiders that own company stock include Art A Garcia, Elanco Animal Health Inc, Jeffrey N Simmons, John P Bilbrey, Michael J Harrington, R David Hoover and Rajeev A Modi.
View institutional ownership trends

How do I buy shares of Elanco Animal Health?

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ELAN) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners